echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Br J Cancer: Anlotinib inhibits the angiogenesis of undifferentiated thyroid cancer by targeting EGFR

    Br J Cancer: Anlotinib inhibits the angiogenesis of undifferentiated thyroid cancer by targeting EGFR

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Thyroid cancer is one of the most common endocrine malignancies, and its incidence is increasing year by year.
    Undifferentiated thyroid cancer (ATC) is the most malignant type of thyroid cancer, although it only accounts for 1-2% of all thyroid cancers.
    However, due to the highly aggressive nature of ATC, it is the main cause of most thyroid cancer-related deaths.

    Thyroid cancer is one of the most common endocrine malignancies, and its incidence is increasing year by year.
    Thyroid cancer is one of the most common endocrine malignancies, and its incidence is increasing year by year.

    Unlike differentiated thyroid cancer, ATC is resistant to surgery, chemotherapy, and isotope intervention.
    According to reports, even with the corresponding targeted therapy, the patient's survival rate has not been improved.


    The occurrence and development of ATC depends on the signal transduction pathway of angiogenesis and is promoted by hypoxic stress.
    Hypoxia-induced angiogenesis is a major survival pathway for malignant tumors.
    HIF1α (hypoxia-inducible factor 1α) is a key regulator involved in oxygen response and also mediates the pathway of crosstalk between tumor and vascular cells.


    The occurrence and development of ATC depends on the signal transduction pathway of angiogenesis and is promoted by hypoxic stress.
    The occurrence and development of ATC depends on the signal transduction pathway of angiogenesis and is promoted by hypoxic stress.
    Blood vessel

    Although hypoxia-induced angiogenesis plays an important role in the occurrence and development of ATC.
    However, the therapeutic potential of broad-spectrum anti-angiogenic agents has not yet been determined.


    Anlotinib is a new type of multi-target receptor tyrosine kinase (RTK) inhibitor, which can block the angiogenesis induced by VEGF/PDGF/FGF.
    This study aims to explore the role of Anlotinib in the ATC hypoxia-induced angiogenesis regulatory network.


    Anlotinib is a new type of multi-target receptor tyrosine kinase (RTK) inhibitor, which can block the angiogenesis induced by VEGF/PDGF/FGF.
    Anlotinib is a new type of multi-target receptor tyrosine kinase (RTK) inhibitor, which can block the angiogenesis induced by VEGF/PDGF/FGF.


    The researchers established a molecular expression lineage through tissue microarrays.
    A variety of measurement methods (tubule formation, 3D germination, and chicken chorioallantoic membrane model) were used to evaluate angiogenesis.


    Anlotinib inhibits hypoxia-activated angiogenesis in ATC

    Anlotinib inhibits hypoxia-activated angiogenesis in ATC

    The results show that under normoxic and hypoxic conditions, Anlotinib can inhibit cell activity in a dose-dependent and time-dependent manner, and can more effectively inhibit hypoxia-activated angiogenesis.
    The researchers found that
    the expression levels of CXCL11 and phosphorylated EGFR were up-regulated and positively correlated under hypoxia.

    Under hypoxia, the expression levels of CXCL11 and phosphorylated EGFR were up-regulated and positively correlated.
    Under hypoxia, the expression levels of CXCL11 and phosphorylated EGFR were up-regulated and positively correlated.


    Further studies have found that cancer cell-endothelial cell crosstalk may be mediated by the positive feedback loop of CXCL11-EGF-EGFR, and Anlotinib can directly target EGFR through a dual mechanism, while inhibiting cancer and endothelial cells.
    Function and block the circuit.
    The AKT-mTOR pathway also participates in this regulatory network.


    Anlotinib can delay the occurrence of tumors in the body

    Anlotinib can delay the occurrence of tumors in the body

    All in all, the results of the study revealed that the discovery of the CXCL11-EGF-EGFR signaling pathway provides a potential molecular mechanism for the interaction between cancer cells and endothelial cells under hypoxia, and EGFR may become a new target and safe Rotinib may be a potential therapeutic candidate for ATC.

    The discovery of the CXCL11-EGF-EGFR signaling pathway provides a potential molecular mechanism for the interaction between cancer cells and endothelial cells under hypoxia, and EGFR may become a new target, and anlotinib may be ATC A potential therapeutic drug candidate.
    The discovery of the CXCL11-EGF-EGFR signaling pathway provides a potential molecular mechanism for the interaction between cancer cells and endothelial cells under hypoxia, and EGFR may become a new target, and anlotinib may be ATC A potential therapeutic drug candidate.


    Original source:


    Liang, J.
    , Jin, Z.
    , Kuang, J.
    et al.
    The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
    Br J Cancer (04 June 2021 ).

    The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.